Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?
Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.
You may also be interested in...
The Canadian specialty pharma has been buying up companies left and right and has plans to continue in 2014, even possibly pursuing a merger of equals in an effort to more than double its market capitalization.
The fast-growing, Canadian specialty pharma will shed thousands of jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.
The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.